JNJ - Johnson & Johnson
| Previous Close | 126.8300 |
| Open | 126.9400 |
| Bid | 126.0600 x 200 |
| Ask | 126.0800 x 100 |
| Day's Range | 125.4100 - 127.4600 |
| 52 Week Range | 122.1500 - 148.3200 |
| Volume | 4,600,150 |
| Avg. Volume | 8,031,553 |
| Market Cap | 337.676B |
| Beta | 0.59 |
| PE Ratio (TTM) | 265.56 |
| EPS (TTM) | 0.4740 |
| Earnings Date | Jul 17, 2018 |
| Forward Dividend & Yield | 3.36 (2.57%) |
| Ex-Dividend Date | 2018-02-26 |
| 1y Target Est | 145.10 |
Yahoo Finance Video•5 hours agoNEWS BITES: Police look for motive in deadly Toronto van attack, President George H.W. Bush hospitalized, Prince's family suing hospital that treated him
Here’s a quick wrap up of other headlines making news today.
Yahoo Finance Video•5 hours agoHere’s why Amazon won’t go into pharma: hedge fund billionaire
Larry Robbins, CEO of Glenview Capital Management, told investors he doesn’t expect Amazon to move into the drug space. Yahoo Finance’s Alexis Christoforous, Melody Hahm, and Julia La Roche discuss his reasoning.
- Market Realist•16 minutes ago
Biktarvy Could Be a Major Driver for Gilead Sciences in 2018
Gilead Sciences (GILD) is planning to launch a novel HIV drug, Biktarvy, in the United States and Europe in 1H18. On February 7, Gilead secured FDA approval for Biktarvy, which is an unboosted integrase strand transfer inhibitor, bictegravir, combined with a dual nucleoside reverse transcriptase inhibitor backbone, Descovy, as an STR (single tablet regimen) for HIV-1 infected patients. Biktarvy, a differentiated HIV-1 regimen
- Market Realist•5 hours ago
How Johnson & Johnson’s Pharmaceutical Segment Performed in 1Q18
About 49.2% of Johnson & Johnson’s (JNJ) total revenues in 1Q18 came from the pharmaceutical segment, making it the largest revenue contributor for the company. The pharmaceutical business includes revenues from cardiovascular and metabolic products, infectious disease products, immunology products, oncology products, neuroscience products, and pulmonary hypertension products.
- Market Realist•6 hours ago
Analyzing Johnson & Johnson’s Segment-Wise Performance in 1Q18
Johnson & Johnson (JNJ) reported 8.4% growth in operating revenues and a 4.2% positive impact of foreign exchange to $20.0 billion in 1Q18 as compared to revenues of $17.8 billion during 1Q17. Johnson & Johnson reported growth across all three of its segments: the pharmaceutical segment, the consumer health segment, and the medical devices segment.
- Market Realist•23 hours ago
Johnson & Johnson’s Revenues Continued to Rise in 1Q18
Johnson & Johnson (JNJ) reported 12.6% growth in its revenues to $20.0 billion during 1Q18 as compared to revenues of $17.8 billion during 1Q17. The company surpassed Wall Street analyst estimates for EPS (earnings per share) and revenues and reported EPS of $2.06 on revenues of $20.0 billion during 1Q18 against estimates for EPS of $2.00 on revenues of $19.4 billion during 1Q17.
- Market Realist•yesterday
Analysts’ Estimates for Eli Lilly & Co.’s 1Q18 Earnings
Eli Lilly & Co. (LLY) is a leading US-based pharmaceutical company with a product portfolio covering human health products and animal health products. Eli Lilly is set to release its 1Q18 earnings on April 24.
- Motley Fool•yesterday
Johnson & Johnson's Top-Line Growth Isn't What It Seems
The company’s double-digit growth comes with some caveats.
- Motley Fool•yesterday
Geron Corporation: The Clock Is Ticking
Geron's stock has been a magnet for short-sellers, but the long thesis remains intact.
- Market Realist•yesterday
Why GlaxoSmithKline’s 1Q18 Revenues Are Expected to Fall
As discussed in the previous article, analysts expect a 2.2% decrease in GlaxoSmithKline’s (GSK) 1Q18 revenues to 7.2 billion pounds due to the impact of divestitures, the negative impact of foreign exchange, and lower sales of some products.
